Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, ...

Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual ...

Eli Lilly has been gaining ground on Novo Nordisk in this sector, intensifying the pressure on the company to innovate and regain market share. The leadership change comes at a crucial time as Novo ...